Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs are expiring, will second generation proteins, the children of the biotech […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!